GGrantIndex
← Search

Protocol Review and Monitoring System

$121,423P30FY2025CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Al B Bensoncontact

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

ABSTRACT – PROTOCOL REVIEW AND MONITORING SYSTEM The Lurie Cancer Center (LCC) has a comprehensive program of research oversight, comprised of separate committees that work collaboratively to ensure robust oversight of all cancer-relevant clinical research. One component of this oversight program is the Protocol Review and Monitoring System (PRMS), which has been continuously approved since 1998. It involves a two-stage review process, comprised of the Disease Teams (DTs) and the Scientific Review Committee (SRC). DTs include members from multiple modalities engaged in research focusing on disease- and/or purpose-oriented clinical trials, and they conduct the first stage of review for new and ongoing clinical trials within their portfolio. The SRC serves as the second stage of review, with a focus on scientific merit, overall prioritization within the LCC, and monitoring of scientific progress. The membership of the SRC consists of a core group, organized into panels, who provide multidisciplinary expertise in clinical oncology research, biostatistics, laboratory-based research, cancer prevention and control, and pharmacy. The SRC is chaired by A.B. Benson III, MD and co-chaired by P. Kumthekar, MD, and M. Kocherginsky, PhD. While DTs communicate and work with the SRC to endorse and monitor research protocols within their area of focus, the SRC maintains sole authority to approve new protocols as well as to close protocols that do not demonstrate adequate scientific progress. During the current term, the SRC changed its procedure for monitoring accrual progress to one where it reviews entire DT portfolios at one time, allowing it to better assess the status of individual studies within the context of the portfolio as a whole. During the current funding period, there have been significant accomplishments and improvements in the PRMS process that have enhanced efficiency, communication, and compliance with NCI requirements.

View original record on NIH RePORTER →
Protocol Review and Monitoring System · GrantIndex